ACADIA Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Catherine Owen Adams

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Catherine Owen Adams (54 yo)

less than a year

Mandato

Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mark Schneyer	Executive VP & CFO	3.2yrs	US$2.59m	0.026% $ 647.8k
Brendan Teehan	Executive VP	3yrs	US$2.62m	0.031% $ 772.9k
Stephen Davis	Consultant	less than a year	US$7.59m	0.11% $ 2.8m
Catherine Owen Adams	CEO & Director	less than a year	Nessun dato	Nessun dato
James Kihara	VP, Chief Accounting Officer & Corporate Controller	4.3yrs	Nessun dato	0.0087% $ 212.7k
Elizabeth Thompson	Executive VP and Head of Research & Development	less than a year	Nessun dato	Nessun dato
Benir Ruano	Senior Vice President of Technical Development	2yrs	Nessun dato	Nessun dato
Albert Kildani	Senior Vice President of Investor Relations & Corporate Communications	1.2yrs	Nessun dato	Nessun dato
Jennifer Rhodes	Executive VP	less than a year	Nessun dato	Nessun dato
Holly Valdiviez	Senior VP & Head of Sales	2.8yrs	Nessun dato	Nessun dato
Rob Ackles	Senior VP & Chief People Officer	2.8yrs	Nessun dato	Nessun dato
Bob Mischler	Senior Vice President of New Product Planning & Strategy	no data	Nessun dato	Nessun dato

2.0yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 0A4W è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Catherine Owen Adams	CEO & Director	less than a year	Nessun dato	Nessun dato
Laura Brege	Independent Director	16.5yrs	US$392.75k	0.012% $ 298.5k
Julian Baker	Independent Director	8.9yrs	US$377.75k	0.062% $ 1.5m
Paul Anderson	Member of the Scientific and Clinical Advisory Board	no data	Nessun dato	Nessun dato
Edmund Harrigan	Independent Director	9yrs	US$387.75k	0.015% $ 380.0k
Daniel Soland	Independent Director	9.7yrs	US$387.75k	0.021% $ 513.2k
Arvid Carlsson	Member of the Scientific and Clinical Advisory Board	no data	Nessun dato	Nessun dato
Carol Tamminga	Member of the Scientific and Clinical Advisory Board	no data	Nessun dato	Nessun dato
Herbert Meltzer	Member of the Scientific and Clinical Advisory Board	no data	Nessun dato	Nessun dato
James Daly	Independent Director	8.8yrs	US$387.75k	0.015% $ 365.1k
Stephen Biggar	Independent Chairman of the Board	11.8yrs	US$432.75k	0.062% $ 1.5m
Elizabeth Garofalo	Independent Director	4.2yrs	US$377.75k	0.014% $ 333.4k

9.0yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0A4W sono considerati esperti (durata media dell'incarico 9 anni).

ACADIA Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ACADIA Pharmaceuticals Inc., Annual General Meeting, May 29, 2024

ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Inc. Announces Executive Changes

Acadia Pharmaceuticals Inc. Announces Management Changes

Doug Williamson to Leave ACADIA Pharmaceuticals Inc. as Executive Vice President, Head of Research and Development

Insufficient new directors

Recent updates

ACADIA Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.20 (vs US$0.007 in 2Q 2023)

ACADIA Pharmaceuticals Inc. Revises Earnings Guidance for the Full Year of 2024

ACADIA Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024

Acadia Pharmaceuticals Inc. Announces the Journal Med Published Results from Two Open-Label Extension Studies, LILAC-1 and LILAC-2

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.10 (vs US$0.27 loss in 1Q 2023)

ACADIA Pharmaceuticals Inc., Annual General Meeting, May 29, 2024

ACADIA Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting

ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year 2024

Full year 2023 earnings released: US$374 loss per share (vs US$1.34 loss in FY 2022)

ACADIA Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 27, 2024

Acadia Pharmaceuticals Inc. Announces Executive Changes

Acadia Pharmaceuticals Inc. Announces Management Changes

Acadia Pharmaceuticals Inc. Initiates Pivotal Phase 3 Study of Carbetocin (Acp-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

Acadia Pharmaceuticals Inc. Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis

Acadia Pharmaceuticals Inc. Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis

Doug Williamson to Leave ACADIA Pharmaceuticals Inc. as Executive Vice President, Head of Research and Development

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.17 loss in 3Q 2022)

ACADIA Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 02, 2023

Insufficient new directors

Acadia Pharmaceuticals Inc. Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc and Encourages Long-Term Acad Investors to Contact the Firm

Second quarter 2023 earnings released: EPS: US$0.007 (vs US$0.21 loss in 2Q 2022)

Acadia Pharmaceuticals Inc. Appoints Kevin R. Oliver as Senior Vice President, Chief Business Officer and Member of Executive Management Committee

ACADIA Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Second Quarter and Third Quarter of 2023

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (Intranasal Carbetocin) for Prader-Willi Syndrome

Nature Medicine Publishes Results from Pivotal Phase 3 Largender Study Evaluating Daybue (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.70 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Full year 2022 earnings released: US$1.34 loss per share (vs US$1.05 loss in FY 2021)

ACADIA Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 27, 2023

ACADIA Pharmaceuticals Inc. Announces Executive Changes

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

Acadia Pharmaceuticals Inc. Provides Sales Guidance for the Full Year of 2022

Acadia Pharmaceuticals Inc. Announces Retirement of Srdjan (Serge) Stankovic as President

ACADIA Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 02, 2022

Acadia Pharmaceuticals Inc Appoints Adora Ndu to Its Board of Directors

ACADIA Pharmaceuticals Inc. Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

No longer forecast to breakeven

ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2021)

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

ACADIA Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 08, 2022

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.41 loss in 1Q 2021)

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for Nuplazid

Insufficient new directors

ACADIA Pharmaceuticals Inc., Annual General Meeting, Jun 07, 2022

ACADIA Pharmaceuticals Inc. to Report Q1, 2022 Results on May 04, 2022

Acadia Pharmaceuticals Inc. Announces Top-Line Results from Phase 2 Study Evaluating Acp-044 for the Treatment of Acute Postoperative Pain

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Acadia Pharmaceuticals Inc. Provides Sales Guidance for the Year 2022

Acadia Pharmaceuticals Inc. Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis

ACADIA Pharmaceuticals Inc. to Report Q4, 2021 Results on Feb 28, 2022

Forecast to breakeven in 2024